Real World Outcomes Study of Hepatic Encephalopathy Patients' Experience on Rifaximin (PROSPER)

NCT02488993 · clinicaltrials.gov ↗

COMPLETED

Status

389

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatic Encephalopathy

Interventions

OTHER: Prospective Phase Rifaximin-α 550mg
OTHER: Prospective Phase No Rifaximin-α 550mg
OTHER: Retrospective Phase

Sponsor

Norgine